Observational studyWorld journal of gastroenterology2025
Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study.
Observational study in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.World journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTofacitinib is an oral, selective Janus kinase inhibitor that is approved for the treatment of ulcerative colitis (UC). The 8-week induction protocol involves the administration of 10 mg twice daily (bid) with the possibility of extending the induction period to 16 weeks. The maintenance dose of tofacitinib is either 5 mg or 10 mg bid.
aimTo assess predictors for clinical remission and drug persistence in patients with UC receiving the extended induction tofacitinib protocol.
methodsThis was a real-world multicenter retrospective study in patients with moderate-to-severe UC. Patients received physician-directed extended induction tofacitinib treatment. We collected clinical and demographic data at baseline and data regarding clinical, laboratory, and endoscopic evaluations, therapeutic modifications, and adverse events at the 52-week follow-up. Possible predictors for clinical remission at week 52 was the primary endpoint. Differences between patients receiving 5 mg bid
resultsThirty-seven consecutive patients from 11 medical centers were included [51.4% males with median age 39 (17-64) years]. Twenty-eight patients continued treatment until week 52 (75.7%) with 67.9% receiving 10 mg tofacitinib; all had prior history of biologic use. We observed that 57.1% of patients achieved clinical remission (66.7% in the 5 mg tofacitinib group and 52.6% in the 10 mg tofacitinib group,
conclusionOur results supported the extended induction strategy with tofacitinib in selected patients with UC. Patients with prior failure of advanced therapies particularly benefitted, highlighting the importance of personalized maintenance regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.